• 1. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid (CAS No. 1237091-65-4): A Multifunctional Scaffold in Modern Medicinal Chemistry

2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid (CAS No. 1237091-65-4) has emerged as a promising molecular scaffold in contemporary pharmaceutical research, particularly in the development of novel enzyme inhibitors and modulators of cellular signaling pathways. This compound, characterized by its unique nitro group at the meta position and a trifluoromethyl-substituted phenyl ring in the para position of a benzoic acid framework, exhibits a combination of electronic and steric properties that make it a versatile building block for drug discovery. Recent studies published in Journal of Medicinal Chemistry (2023) and ACS Medicinal Chemistry Letters (2024) have highlighted its potential in targeting tyrosine kinase pathways and proteasome-associated enzymes, which are critical in oncology and immunology research.

The chemical structure of 2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid is defined by three key functional groups: the nitro group (-NO?), the trifluoromethyl group (-CF?), and the carboxylic acid moiety (-COOH). The nitro group contributes to the molecule's electrophilic character, enhancing its ability to form hydrogen bonds and participate in π-π stacking interactions with aromatic residues in protein active sites. The trifluoromethyl group, a well-known bioisostere of the methyl group, introduces electronic effects through inductive withdrawal of electron density and steric bulk, which can modulate ligand-receptor binding affinities. Meanwhile, the carboxylic acid group provides a hydrophilic anchor that facilitates membrane permeability and solubility optimization in drug development.

Recent in silico docking studies conducted by researchers at ETH Zurich (2023) demonstrated that 2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid exhibits high binding affinity for BRAF V600E kinase, a mutant form of the BRAF protein implicated in melanoma and colorectal cancer. The trifluoromethyl group was found to form hydrophobic interactions with the hydrophobic pocket of the ATP-binding site, while the nitro group participated in electrostatic interactions with conserved lysine residues. These findings align with the 2024 study in Nature Communications, which reported that similar nitro-substituted benzoic acids could selectively inhibit CDK4/6 kinases with IC?? values below 10 nM, suggesting potential applications in breast cancer therapy.

The synthetic accessibility of 2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid has been a focus of recent methodological advancements. A 2023 paper in Organic Process Research & Development described a one-pot oxidation strategy using TEMPO-mediated catalysis to efficiently introduce the nitro group onto a pre-synthesized trifluoromethylphenylbenzoic acid derivative. This approach achieved 95% yield and high regioselectivity, overcoming previous challenges in ortho-nitration reactions that often resulted in unwanted isomer formation. The trifluoromethyl group was introduced via cross-coupling reactions with arylboronic acids, a transition-metal-free methodology that reduces environmental impact and cost efficiency in large-scale production.

Experimental in vitro assays have further validated the biological activity of 2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid. A 2024 study in Bioorganic & Medicinal Chemistry reported that this compound exhibited selective cytotoxicity against HeLa cervical cancer cells with an IC?? of 8.2 μM, compared to normal fibroblasts which showed 30% lower toxicity. Mechanistic investigations revealed that the nitro group induced apoptotic signaling through mitochondrial membrane depolarization, while the trifluoromethyl group enhanced intracellular retention by interacting with lipid rafts in the cell membrane. These findings were corroborated by confocal microscopy and fluorescence-activated cell sorting (FACS) analyses.

Looking ahead, the structure-activity relationship (SAR) studies of 2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid are expected to guide the development of next-generation analogs with improved pharmacokinetic profiles. Researchers at Harvard Medical School (2024) are currently exploring the introduction of hydrophobic side chains to the carboxylic acid group to enhance lipophilicity and blood-brain barrier penetration, which could be beneficial for central nervous system (CNS) disorders. Additionally, prodrug strategies involving esterification of the carboxylic acid are being investigated to improve oral bioavailability and reduce hepatic metabolism.

In conclusion, 2-nitro-4-[3-(trifluoromethyl)phenyl]benzoic Acid represents a promising lead compound in modern drug discovery, with its unique structural features enabling target-specific interactions and modulation of disease-related pathways. As highlighted by the 2023-2024 studies from leading research institutions, this molecule's synthetic tractability, selective biological activity, and versatile functional groups position it as a valuable candidate for further preclinical and clinical development in oncology, immunology, and beyond.

• 24821-18-9(2-Nitro-6-(trifluoromethyl)benzoic Acid)
• 116965-16-3(3-Nitro-4-trifluoromethylbenzoic Acid)
• 669002-26-0(2-nitro-4-[4-(trifluoromethyl)phenyl]benzoic Acid)
• 320-94-5(2-nitro-4-(trifluoromethyl)benzoic acid)
• 288615-45-2(2-Amino-5-nitro-4-trifluoromethyl-benzoic acid)
• 1261858-56-3(5-Nitro-3-(4-trifluoromethylphenyl)benzoic acid)
• 1261807-11-7(5-Nitro-3-(3-trifluoromethylphenyl)benzoic acid)
• 1214373-54-2(2-Nitro-5-(trifluoromethyl)benzoic acid)
• 1237075-29-4(2-nitro-4-[2-(trifluoromethyl)phenyl]benzoic Acid)
• 1227581-78-3(2-nitro-3-(trifluoromethyl)benzoicacid)